Amendments to the Claims:

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1–14. (Canceled)

15. (Currently Amended) Method of treatment of a disease involving a neuronal connectivity defect comprising administering to an individual in need thereof a therapeutic effective amount of ~~one~~ an epothilone or ~~derivative~~ pharmaceutically acceptable salt thereof.

16. (Currently Amended) Method according to claim 15, wherein the disease ~~includes~~ is a psychotic or psychiatric disorder.

17. (Currently Amended) Method according to claim 15, wherein the epothilone is a compound of formula (I) or a pharmaceutically acceptable salt thereof:



(I)

wherein:

R^1 represents H, alkyl, alkenyl or alkynyl in C_1-C_6, aryl in C_6-C_{10}, or aralkyl in C_7-C_{15},

R^2, R^3 each represents ~~each~~ H or form together a C=C double bond,

R^4 represents H, a C_1-C_6-alkyl ~~in particular CH_3~~, or a fluoro substituted C_1-C_6 alkyl ~~in particular CF_3 or CFH_2~~,

R^5 and R^6 form a C=C double bond or a ~~three membered~~ three-member ring including O, S, NR^7, or CR^8R^9 ~~with~~ where:

R^7 ~~being~~ is $C(O)R^{10}$[[,]] or SO_2R^{10}, and

R^8, R^9, and R^{10} ~~being~~ each independently represent H, a halogen, a C_1-C_6 alkyl, a C_6-C_{10} aryl, or a C_7-C_{15} alkaryl,

R^{11} ~~being~~ represents H, a C_1-C_6 alkyl, a C_6-C_{10} aryl, or a C_7-C_{15} alkaryl, ~~and in particular H,~~

W represents $C(R^{12})$=CH, $C(R^{12})$=$C(CH_3)$, $C(R^{12})$=CF or a bicyclic aromatic/heteroaromatic radical ~~preferably a 2-methylbenzothiazol-5-yl radical, or a 2-methylbenzoxazol-5-yl radical or a quinolin-7-yl radical~~, with R^{12} representing a heteroaromatic radical, ~~preferably a 2-pyridinyl, a 2-substituted thiazol-4-yl or a 2-substituted oxazol-4-yl radical with substitution in 2-position by~~

~~C_1-C_6-alkyl,~~

~~pseudohalogen like CN or N_3,~~

~~S-C_1-C_4-alkyl,~~

~~O-C_1-C_6-alkyl, or~~

~~C_1-C_6-alkyl substituted by OH, amino, halogen, pseudohalogen such as NCO, NCS, N_3, O-(C_1-C_6)-acyl, O-(C_1-C_6)-alkyl or O-benzoyl,~~

X-Y represents O-C(=O), O-CH_2 , CH_2-O, or CH_2-C(=O),

Z represents C=O, S, S=O, or SO_2, and

R^{13} and R^{14} represents independently from each other H, C_1-C_6-alkyl, (CO)R^{15}, or C_{1-4}-trialkylsilyl, with R^{15} being H, a C_1-C_6-alkyl, or a fluoro substituted C_1-C_6-alkyl~~, and pharmaceutically acceptable salts thereof~~.

18. (Currently Amended) Method according to claim 15, wherein the epothilone is a ~~derivative~~ compound of following formula (II) or a pharmaceutically acceptable salt thereof:



(II)

wherein:

R'^{4} represents ~~an~~ a C_1-C_6 alkyl or substituted C_1-C_6 alkyl with substituents selected from the group consisting of ~~as~~ F, Cl, Br, ~~or~~ I, ~~pseudohalogen, such as~~ –NCO, -NCS, $–N_3$, NH_2, OH, O-(C_1-C_6)-acyl, O-(C_1-C_6)-alkyl, and ~~or~~ O-benzoyl,

R'^{1} and R'^{2} are independently from each other H, a C_1-C_6-alkyl, (CO)R'^{5} with R'^{5} being H, a C_1-C_6-alkyl, a C_1-C_6-fluoroalkyl, or a C_{1-4}-trialkylsilyl,

R'^{3} represents H, C_1-C_6-alkyl, or a halogen substituted C_1-C_6-alkyl, and

Y and Z form either a C=C double bond or are ~~the~~ an O atom of an epoxide ~~and pharmaceutically acceptable salts thereof~~.

19. (Currently Amended) Method according to claim 18, wherein ~~the epothilone is at least a derivative of formula (II) wherein~~ R'^{1}, R'^{2}, and R'^{3} represents independently from each other, H, a C_1-C_6-alkyl ~~in particular CH_3~~, or a C_1-C_6 fluoroalkyl ~~in particular CF_3 and Y and Z form either a C=C double bond or are together the O atom of an epoxide~~.

20. (Currently Amended) Method according to claim 15, wherein epothilone ~~includes~~ is at least ~~the~~ a natural epothilone A or B ~~of~~ represented by the following ~~formula~~ structural formulas:



Epothilone A



Epothilone B

or a pharmaceutically acceptable salt thereof.

21. (Currently Amended) Method according to claim 15, wherein epothilone ~~includes~~ is at least one synthetic epothilone C, D, E or F ~~of~~ represented by the following ~~formula~~ structural formulas:



Epothilone C



Epothilone D



Epothilone E



Epothilone F

~~in particular epothilone D~~ and pharmaceutically acceptable salts thereof.

22. (Currently Amended) Method according to claim 15, wherein epothilone ~~includes~~ is at least one synthetic epothilone ~~of~~ represented by the following ~~formula~~ structural formulas:










23 (Currently Amended) Method according to any claim 15, wherein the epothilone or pharmaceutically acceptable salt thereof is used at a therapeutically effective amount from ~~about~~ 0.01 mg/Kg/dose to ~~about~~ 100 mg/Kg/dose.

24. (Currently Amended) Method according to claim 15, wherein the epothilone or ~~derivative~~ pharmaceutically acceptable salt thereof is administered in a pharmaceutical composition comprising at least a pharmaceutically acceptable carrier.

25. (New) Method according to claim 15, wherein the epothilone is synthetic epothilone D or a pharmaceutical salt thereof.